| UNIVERSITE ' CLAUDE BERNARD DE LYON 1 Patent applications |
| Patent application number | Title | Published |
|---|
| 20110318355 | MUTANT PROTEINS OF THE F PROTEIN OF PIV-5 AND PIV-2 - The present application concerns mutant proteins of the fusion protein (F protein) of the parainfluenza virus (PIV) which are currently indexed as type 5 PIV (PIV-5 or PIV5) and type 2 PIV (PIV-2 or PIV2). The present application concerns products deriving therefrom, such as: nucleic acids, vectors, cells, fusion inhibitors of the antibody, aptamer, interfering RNA type; myelomas, hybridomas; stem and progenitor cells. The present application also concerns mutant proteins and products derived therefrom for use in medical and biotechnological applications. | 12-29-2011 |
| 20110311541 | MUTANT PROTEINS OF THE F PROTEIN OF PIV-5 AND PIV-2 - The present application concerns mutant proteins of the fusion protein (F protein) of the parainfluenza virus (PIV) which are currently indexed as type 5 PIV (PIV-5 or PIV5) and type 2 PIV (PIV-2 or PIV2). The present application concerns products deriving therefrom, such as: nucleic acids, vectors, cells, fusion inhibitors of the antibody, aptamer, interfering RNA type; myelomas, hybridomas; stem and progenitor cells. The present application also concerns mutant proteins and products derived therefrom for use in medical and biotechnological applications. | 12-22-2011 |
| 20110281862 | ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL - The present invention relates to compounds of formula (I) | 11-17-2011 |
| 20110144314 | METHOD FOR SELECTIVELY EXTRACTING MEMBRANE PROTEINS USING CALIXARENES - The present invention relates to a method for selectively extracting membrane proteins using at least one calixarene of formula (I). The use of calixarenes in the method according to the invention enables the selective solubilization of the membrane proteins while preserving the three-dimensional structure that is essential to the enzymatic activity thereof. | 06-16-2011 |
| 20110112110 | ANTIPROLIFERATIVE COMPOUNDS AND THERAPEUTIC USES THEREOF - Inhibitors of the oncogenic tyrosine kinase ALK and of the Bcr-Abl mutant T315I Bcr-Abl, pharmaceutical compositions containing the same and their use for the treatment of hyper-proliferative diseases. | 05-12-2011 |
